HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Clinical experience with tiapride in the treatment of extrapyramidal syndromes].

Abstract
Tiapride was given at an average dosage of 300-900 mg per day, intramuscularly for the first three days, then by oral route, to 62 patients with abnormal movements of various types. The best responses were recorded in chorea and bucco-lingua-facial dyskinesia as well as in dyskinetic movements induced by levo-dopa in Parkinson patients. Clinical and biological tolerance of tiapride was excellent, with only one case of drowsiness and two cases of galactorrhea.
AuthorsE Csanda, F Fornadi
JournalLa semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris (Sem Hop) Vol. 58 Issue 45 Pg. 2647-50 (Dec 09 1982) France
Vernacular TitleExpérience clinique du tiapride dans le traitement des syndromes extrapyramidaux.
PMID6297061 (Publication Type: English Abstract, Journal Article)
Chemical References
  • Benzamides
  • Tiapamil Hydrochloride
Topics
  • Basal Ganglia Diseases (drug therapy)
  • Benzamides (therapeutic use)
  • Humans
  • Tiapamil Hydrochloride (adverse effects, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: